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Accepted 20 February 2019Objectives: To evaluate safety outcomes from clinical studies of a 12-month contraceptive vaginal system (CVS) re-
leasing an average of segesterone acetate (SA) 150 mcg and ethinyl estradiol (EE) 13 mcg daily.
Study design:We integrated clinical safety data from nine studies in which women used the CVS for 21 consecutive
days and removed it for 7 days of each 28-day cycle. Four studies used the ﬁnal manufactured CVS, including a 1-
year pharmacokinetic study, two 1-year phase 3 trials and a second-year treatment extension study. We assessed
safety by evaluating adverse events women reported in a daily diary. We also included data from focused safety
studies evaluating endometrial biopsies, vaginal microbiology and liver proteins from one of the phase 3 studies.
Results: The combined studies included 3052 women; 2308 women [mean age 26.7±5.1 years; mean body mass
index (BMI) 24.1±3.7 kg/m2] received the ﬁnal manufactured CVS, of whom 999 (43.3%) completed 13 cycles of
use. Women using the ﬁnal CVS most commonly reported adverse events of headache (n=601, 26%), nausea
(n=420, 18%), vaginal discharge/vulvovaginal mycotic infection (n=242, 10%) and abdominal pain (n=225,
10%). Few (b1.5%)women discontinued for these complaints. Four (0.2%)women experienced venous thromboem-
bolism (VTE), three of whom had risk factors for thrombosis [Factor V Leidenmutation (n=1); BMIN29 kg/m2 (n=
2)]. During 21,482 treatment cycles in the phase 3 studies evaluable for expulsion, women reported partial expul-
sions in 4259 (19.5%) cycles and complete expulsions in 1509 (7%) cycles, most frequently in the initial cycle
[499/2050 (24.3%) and 190/2050 (9.3%), respectively]. Safety-focused studies revealed no safety concerns.
Conclusion: The 1-year SA/EE CVS has an acceptable safety proﬁle. Additional studies arewarranted in obesewomen
at higher risk of VTE.Keywords:
Contraceptive vaginal system
Nestorone
Segesterone acetate
Ethinyl estradiol
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Table 1
SA/EE CVS safety analysis studies
Population/analysis set
All-dose SA/EE CVS
All SA/EE 150/13b CVS
Phase 3 trials SA/EE 150/13b CVS
The all-dose SA/EE CVS dataset (n=2843) and the SA/EE 1
dataset (n=2308) are used as the denominator for the pi
a Formulation intended for marketing.
b In vitro release data initially supported an average dai
respectively.
324 K. Gemzell-Danielsson et al. / Contraception 99 (2019) 323–328Implications: This 1-year contraceptive vaginal system represents a new long-term, user-controlled and procedure-
free option with a safety proﬁle similar to other combination hormonal contraceptives. The same precautions cur-
rently used for combination hormonal contraceptive prescriptions apply to this new contraceptive vaginal system.
© 2019 Elsevier Inc. All rights reserved.1. Introduction
Segesterone acetate (SA), also known as Nestorone®, is a novel 19-
nor-progesterone that is inactive orally but highly effective when ad-
ministered via implantable, vaginal and transdermal systems [1]. Like
progesterone, SA binds speciﬁcally to progesterone receptors but not
to androgen or estrogen receptors, thus limiting undesired androgen,
antiandrogen or estrogenic effects [2]. Although SA binds to the gluco-
corticoid receptor, no glucocorticoid-related effects appear at therapeu-
tic doses [2]. SA does not transactivate the androgen receptor, and its
metabolites do not interact with the GABA-A receptor [3]. This latter
ﬁnding could theoretically avoid mood changes and sleepiness de-
scribed with progesterone treatment related to allopregnanolone (the
main progesterone metabolite) action on the GABA-A receptor [3].
The Population Council developed an SA/ethinyl estradiol (EE) con-
traceptive ring with a ﬁnal formulation delivering an average of SA 150
mcg and EE 13 mcg daily. The US Food and Drug Administration ap-
proved this product as a contraceptive vaginal system (CVS) in April
2018. Women used the CVS for 21 consecutive days and then removed
it for 7 days in each 28-day cycle for all studies. Women can use the
same CVS for up to 13 cycles (1 year). The CVS requires minimal to no
daily attention and can be inserted or removedwithout a trained health
provider. This report summarizes the safety data from twophase 3 stud-
ies and seven other clinical studies that included a broad range of
women at United States (US) and non-US sites.
2. Methods
The overall safety evaluation plan for the SA/EE 150/13 CVS program
included phase 1 and 2 studies of multiple doses of pilot formulations
manufactured by the Population Council (New York, NY, USA) and
two phase 3, 13-cycle studies (ClinicalTrials.gov as NCT00455156 and
NCT00263341) with the ﬁnal formulation manufactured by QPharma
(Malmö, Sweden), a US-only study at 15 sites, and a multinational
study at 12 US and non-US sites. The US-only study included three fo-
cused, safety substudies at speciﬁc sites, which assessed vaginal micro-
biology [4], endometrial changes and coagulation factor changes [5] in
addition to the primary efﬁcacy and safety endpoints. A drug–drug in-
teraction study tested the effects of miconazole formulations on EE
and SA vaginal absorption [6]; a pharmacokinetic (PK) study compared
EE exposure between the pilot SA/EE 150/13 CVS and an approved levo-
norgestrel (LNG) 150 mcg/EE 30 mcg oral contraceptive during one
cycle of use; and a 3-month, pharmacodynamic (PD), phase 1 studyProduct studied
Phase 3a and Pilot SA/EE CVS
Phase 3a and Pilot SA/EE CVS
Phase 3 SA/EE CVSa
50/13 CVS dataset (n=2569) are use
votal trial AEs and laboratory assessm
ly release of 150/15mcg/day for SA ancompared the impact of EE on hepatic proteins with oral versus vaginal
delivery [7]. Finally, a 13-cycle, phase 2, dose-ﬁnding study of the pilot
SA/EE 150/13 CVS evaluated vaginal and cervical epithelium by colpos-
copy [8,9]. The institutional review boards (IRBs) of the Population
Council and one contracted by the National Institute of Child Health
and Human Development's Contraceptive Clinical Trials Network Coor-
dinating Center (Advarra, Columbia, MD 21046), and each participating
site's IRB or Ethical Committee approved the protocols. All subjects
signed written informed consent prior to initiating any study
procedures.
The two phase 3, multicenter, single arm, open-label studies, con-
ducted from 2006 to 2009, were identically designed and provided
most of the safety information. Participants were healthy, sexually ac-
tive, nonpregnant, nonsterilized women 18–40 years old. Subjects re-
ported AEs, concomitant medications and CVS expulsions (partial or
complete) on diary cards (see deﬁnitions in Supplemental Information).
During the ﬁrst 6months of study enrollment, two venous thromboem-
bolic events (VTEs) occurred in women who had a baseline body mass
index (BMI) N29.0 kg/m2 in the US-only study. The Data SafetyMonitor-
ing Board recommended limiting further enrollment to women with
baseline BMI ≤29.0 kg/m2 and to discontinue women in the two studies
with BMI N29.0 kg/m2. An additional open-label investigation collected
PK and PD data from 39 subjects during cycles 1, 3 and 13 and safety
data from all cycles of this study (see Supplemental Information). The
safety data of this PK/PD study were part of each pooled dataset.
For the overall integrated safety summary analysis, we created three
pooled datasets of SA/EE CVS use (Table 1). Investigators graded relat-
edness of AEs to CVS use as possibly, probably or deﬁnitely/highly prob-
ably (Supplemental Table 1S).
In a multicenter substudy of the US phase 3 study, investigators en-
rolled 156 women to evaluate endometrial safety of the SA/EE 150/13
CVS for 13 cycles. Subjects had a baseline endometrial biopsy between
days 7 and 14 of the screening cycle for women not currently using
combination hormonal contraceptives (CHCs) or at any time prior to
initiating the CVS for women using CHCs. Investigators excluded
women whose screening biopsies showed hyperplasia or other anoma-
lies. The ﬁrst 25 women had a second endometrial biopsy at cycle 6
(days 20–24), and the remaining women had a second biopsy at cycle
13 (days 20–24) or at early termination if enrolled for at least
3 months. Three blinded, independent, board-certiﬁed pathologists
read each of the biopsies.
We performed all statistical analyses using SAS® version 9.2 or
higher.We used descriptive statistics to summarize the safety variables.Doses studied (mcg/day) Total subjects
50/10
50/20
150/13
150/20
200/13
2843
150/13 2569
150/13 2308
d as the denominator for program-wide SAE assessments, and the phase 3 trials SA/EE CVS
ents.
d EE, respectively. Estimates from an ex vivo study indicate 150/13mcg/day for SA and EE,
Table 2
Subject disposition in the phase 3 trials (n=2308) analysis set of women using the SA/EE CVS, and reasons for discontinuation
Disposition All-dose SA/EE CVS
(n=2843)
Phase 3 SA/EE 150/13 CVS
(n=2308)
Phase 3 SA/EE 150/13 CVS BMI subgroups
≤29.0 kg/m2 (n=2099) N29.0 kg/m2 (n=209)
Completed the study 1761 (62) 1332 (58)a 1296 (62) 36 (17)
Discontinued prematurely 1082 (38) 976 (42) 803 (38) 173 (83)
AEb 328 (12) 281 (12) 267 (13) 14 (7)
Withdrew consent 228 (8) 214 (9) 191 (9) 23 (11)
Lost to follow-up 220 (8) 197 (9) 184 (9) 13 (6)
Eligibilityc 147 (5) 147 (6) 31 (1) 116 (56)
Pregnancy 63 (2) 54 (2) 50 (2) 4 (2)
Compliance 62 (2) 49 (2) 47 (2) 2 (b1)
Expulsions 33 (1) 33 (1) 32 (2) 1 (b1)
Other 3 (b1) 1 (b1) 1 (b1) 0
All data are presented as n (%).
a A total of 1332 completed the study and 999 completed the 13 cycles of CVS use. Not all completers whowere enrolled late in the study completed 1 year due to the expiration of the
drug.
b Most common AEs leading to discontinuation: headache 30 (1.3%), nausea 28 (1.2%), vaginal discharge/vulvovaginal mycotic infection 30 (1.3%) and abdominal pain 30 (1.3%).
Metrorrhagia/menorrhagia occurred in 7% of the subjects, and 1.7% discontinued for this reason (n=39).
c The data safety monitoring board recommended discontinuation of subjects with a BMI N29.0 kg/m2 during the study.
Table 3
Demographics and baseline characteristics of SA/EE CVS users in clinical trials
Characteristic All-dose SA/EE
CVS
(n=2843)
Phase 3 trials SA/EE 150/13 CVS
(n=2308)
Age (years) 27.0±5.2 26.7±5.1
Age category
18–19 166 (6) 144 (6)
20–24 992 (35) 852 (37)
25–29 914 (32) 757 (33)
30–35 553 (19) 393 (17)
≥36 218 (8) 162 (7)
Parity
0 1670 (59) 1478 (64)
≥1 1173 (41) 830 (36)
Region
USA 1723 (61) 1536 (67)
Europe 411 (14) 309 (13)
Non-USA and
non-Europe
709 (24.9) 463 (20.1)
Weight (kg) 64.5±11.0 64.3±10.6
BMI (kg/m2) 24.3±3.9 24.1±3.74
≤20.0 317 (11) 251 (11)
0.1–25.0 1485 (52) 1245 (54)
25.1–27.0 414 (15) 339 (15)
27.1–29.0 320 (11) 264 (11)
N29.0 307 (11) 209 (9)
Race
Asian 82 (3) 82 (4)
African ancestry 328 (12) 328 (14)
Caucasian 1670 (59) 1638 (71)
Other 250 (9) 248 (11)
Unknown 513 (18) 12 (b1)
Ethnicitya
Hispanic or Latina 701 (25) 690 (30)
Not Hispanic or Latina 1641 (58) 1618 (70)
Unknown 501 (18) 0
All data are presented as n (%) or mean ± standard deviation.
The analysis sets are deﬁned in Table 1. The all SA/EE 150/13 CVS analysis set includes all
subjects in the phase 3 trial analysis set and is a subset of the all-dose SA/EE CVS analysis
set.
a Ethnicity was captured on the case report form (CRF) using the word “Latino” for
phase 3 studies; only “not Hispanic” or “Hispanic” was captured on the CRF of phase 2
studies. Ethnicity was not captured for any other study.
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The all-dose SA/EE CVS dataset included 2843womenwho used one
of ﬁve SA/EE CVS doses for 1 to 13 cycles (Table 2). Among the 2308
women enrolled in the phase 3 trials, 1332 (58%) women completed
the study, and 999 completed 13 cycles (1 year) of use (Table 2). Of
the 976 (42%) subjects who discontinued early, the most common rea-
sons were an adverse event (AE; n=281, 12%), withdrawal of consent
(n=214, 9%) and loss to follow up (n=197, 9%). Among the 214 (9%)
women who withdrew consent, personal reasons were the most com-
mon reason for discontinuation (22%–78% depending on country). The
change in eligibility related to BMI resulted in 147 (6%) women
discontinuing early. Overall, investigators enrolled 209 women with
BMI N29.0 kg/m2 of whom 36 (17.2%) completed 13 cycles. The disposi-
tion of subjects in the supportive analysis sets was generally similar.
For the 2308 women in the phase 3 analysis set, most were
20–29 years (n=1609, 70%); range for all was 18.1–40.8 years
(Table 3). About two thirds (n=1584, 69%) had a BMI of 20.1 to
27.0 kg/m2, and most (n=1638, 71%) were Caucasian (Table 3). Demo-
graphics for the all-dose dataset were similar.
3.1. Overview of AEs
In the phase 3 trial analysis set, 2016women (87%) reported at least
one AE; most were considered mild or moderate in severity. Table 4
summarizes the most common adverse reactions (treatment-related
and treatment-emergent AEs; occurring in N2% of subjects). Overall,
1602 (69%) women experienced AEs considered related to CVS use.
Table 2S summarizes all AEs based on BMI. Two hundred eighty-one
women (12%) discontinued due to AEs (Table 2).
Among women in the all-dose dataset (n=2843), 51 (2%) women
experienced 55 serious AEs (SAEs). Sixteen SAEs occurred in more
than 1 subject, including 4 VTEs, 2 allergic reactions and 10 spontaneous
abortions. In the phase 3 trials, 47 SAEs occurred in 43 (2%) subjects. In-
vestigators assessed 15 of these SAEs as possibly or probably related to
the CVS. No SAEs occurred in more than 1 subject among 209 SA-only
CVS participants. In the all-dose CVS analysis set (n=2843), ﬁve sub-
jects reported gallbladder disease; two were considered serious, and a
third resulted in a cholecystectomy. No reported pregnancies resulted
in fetal anomalies and no deaths occurred in any study.
3.2. Venous thromboembolic events
Four nonfatal VTEs occurred at US study sites during a total exposure
of 2021 woman-years (WY); all four subjects recovered. These events
included one pulmonary embolism, two deep vein thromboses andone cerebral venous thrombosis that occurred in cycles 2, 3, 6 and 7, re-
spectively. Three of these cases occurred in women with risk factors for
VTEs: two subjects had high baseline BMI (29.1 and 30.8 kg/m2), and
one 39-year-old woman had Factor V Leiden heterozygous mutation
discovered after the event. The fourth case occurred in a 28-year-old
woman with a BMI of 25.2 kg/m2 who withdrew from the study before
a clotting evaluation could be conducted. She reported smoking b10
Table 4
Adverse reactionsa occurring in N2% of subjects: phase 3 trial SA/EE CVS analysis set
(n=2308)
Adverse reaction Subjects, n (%)
Any event 1602 (69)
Headache 601 (26)
Nausea 420 (18)
Vaginal discharge 242 (10)
Uterine spasm 225 (10)
Vulvovaginal mycotic infection 173 (7)
Metrorrhagiab 160 (7)
Breast tenderness 134 (6)
Vomiting 108 (5)
Genital pruritus female 92 (4)
Urinary tract infection 92 (4)
Migraine 77 (3)
Vaginal candidiasis 70 (3)
Libido decreased 69 (3)
Acne 66 (3)
Mood swings 60 (3)
Dizziness 58 (3)
Dyspareunia 56 (2)
Vulvovaginal discomfort 56 (2)
Withdrawal bleedc 56 (2)
Breast pain 49 (2)
Discontinuation rates for the common adverse reactions were as follows: headache in-
cluding migraine n=30 (1.3%), vaginal discharge/vulvovaginal mycotic infections n=30
(1.3%), nausea/vomiting n=28 (1.2%) and metrorrhagia/menorrhagia n=39 (1.7%).
a Includes treatment-emergent AEs considered possibly, probably or deﬁnitely related
to treatment.
b Metrorrhagia includes verbatim terms of irregular bleeding, irregular spotting,
breakthrough bleeding, breakthrough spotting, spotting, frequent spotting and prolonged
spotting.
c Withdrawal bleed includes verbatim terms of heavy bleeding with menses, bleeding
very much, prolonged bleeding with menses and frequent bleeding with menses.
Table 5
Change from baseline of vital signs data: SA/EE 150/13 CVS analysis set (n=2308)
Vital signs Baseline mean (SD) Median change (min/max)
Diastolic BP (mmHg) 68.7 (7.7) 0.5 (−28/30a)
Systolic BP (mmHg) 108.4 (10.1) 1.0 (−37/40a)
Pulse (bpm) 73.9 (10.3) 2.0 (−42/47)
Weight (kg) 64.3 (10.6) 0.2 (−17b/17.7c)
BMI (kg/m2) 24.1 (3.7) 0.09 (−6.6/6.6)
BP, blood pressure; min, minimum; max, maximum.
a Eight subjects reported hypertension as an AE (veriﬁed by the staff), and four of them
received short-term antihypertensive treatment. Only one of these discontinued for hy-
pertension of 132/102.
b Three subjects reported weight decrease as an AE.
c Thirty-ﬁve subjects reported weight increase as an AE; nine of these discontinued for
the weight increase of 4–10 kg, and 1 of these was discontinued for BMI N29.0.
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(US and international sites) with a BMI b29.0 kg/m2, the VTE rate was
10.8/10,000 WY [95% conﬁdence interval (CI), 8.9–13.1]. No VTEs oc-
curred among the 1120 (48%) of subjects enrolled in non-US sites.
3.3. CVS expulsions
Of the 2308 women in the phase 3 studies, 2096 (90.8%) had
evaluable diary responses for expulsion. Overall, 1107 of the 2096
(52.8%) subjects reported at least one complete (24.6%) or partial expul-
sion (44.0%) during CVS use. Users reported CVS expulsion most fre-
quently in the ﬁrst cycle of use. Among the 2050 women who
documented expulsion during the ﬁrst cycle, 190 (9.3%) and 499
(24.3%) experienced complete and partial expulsions, respectively.
When including all 21,842 treatment cycles eligible for expulsion anal-
ysis, complete expulsion occurred in 1509 (7.0%) cycles and partial ex-
pulsion in 4259 (19.5%) cycles. Only 115 of the 2096 (5.5%) of women
required a replacement system due to a lost CVS.
3.4. Clinical laboratory values
No changes in measured clinical laboratory values occurred from
baseline to end of treatment in 57% to 80% of the women in the phase
3 studies. Minimal, but not clinically relevant, changes in blood urea ni-
trogen, creatinine, hemoglobin and lipids occurred in the remaining
women.Of these, 13 (0.6%) subjects had elevations of a single liver func-
tion test above normal at baseline, 11 of which improved during CVS
use. Fifteen (0.6%) other subjects developed nonclinically signiﬁcant el-
evations during therapy for at least one liver function test; none re-
sulted in discontinuation.
Subjects had a median change in total cholesterol from baseline to
end of study of +0.23 mmol/L. Median changes from baseline to end
of study were +0.16 mmol/L for high-density lipoprotein, 0 mmol/L
for low-density lipoprotein and +0.15 mmol/L for triglycerides.Meanhemoglobin and hematocrit values remained stable. Themean
change in hemoglobin from baseline to end of study was−2.7±8.3 g/L.
3.5. Vital signs and physical exam
Most subjects had normal vital signs at both assessments (Table 5).
At baseline among participants at non-US and US sites, mean weight
was 62.2±9.2 kg and 65.4±11.0 kg, respectively, and mean BMI was
23.6±3.2 kg/m2 and 24.4±4.0 kg/m2, respectively. The mean change
in BMI from baseline to end of treatment was 0.1±1.2 kg/m2; mean
weight change was 0.4±3.3 kg. While investigators did not report any
clinically relevant weight changes, 35 women reported weight increase
as an AE. Eight women reported hypertension as an AE, all veriﬁed by
medical staff, and one of those discontinued. Investigators also reported
no clinically relevant changes in physical exam data from baseline to
study end.
3.6. Endometrium
Seven women with hyperplasia (n=2), endometritis (n=1) and
polyps (n=4) at baseline were excluded. Eighty-three subjects had
end-of-treatment, follow-up biopsies. No endometrial hyperplasia or
carcinoma was found. Secretory and atrophic/inactive tissues were the
most common diagnoses.
4. Discussion
Data collated from the SA/EE CVS clinical trials demonstrate a safety
proﬁle as expected for a CHC containing EE,with no unexpected safety sig-
nals. Headache and nausea were among the most common adverse reac-
tions; these AEs are also commonly reported with other CHCs. A few
cases of gallbladder disease, also known to occur with estrogen use, were
not unexpected. Whereas mood disorders have been reported with CHC
use at rates up to 24% [10], only 3% of CVS users complained of mood
swings. Lastly, we noted no safety concerns in the standard laboratory
chemistry, hematology, vital signs or physical examination ﬁndings.
Three other safety studies have been published on the CVS [4,6,8,9]. A
13-cycle, multicenter, randomized, dose-ﬁnding study of the pilot rings
evaluated 150 healthy, reproductive-age women using cervical and vagi-
nal colposcopic examinations at cycles 3 and 13, ﬁnding no safety con-
cerns with any dose [8,9]. In addition, co-administration of miconazole
suppositories with the CVS led to higher systemic exposure of both SA
and EE, while a miconazole cream did not affect hormone levels [6].
Thus, women using the SA/EE CVS may be advised to use an oral or
cream formulation of miconazole rather than a suppository to treat vagi-
nal candidiasis. Lastly, a single-center, microbiology substudy did not ﬁnd
any increase in vaginal infection incidence or clinically signiﬁcant change
in vaginal ﬂorawith use of the SA/EE 150/13 CVS for up to 13 consecutive
cycles [4]. Cultures of the used CVS and those from vaginal ﬂuid had sim-
ilar prevalence and concentrations of microorganisms [4].
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study participants. Although it may suggest some unreported AEs, the
reasons for withdrawal of consent were mainly personal such as being
no longer sexually active, relocation and desiring pregnancy. Nonethe-
less, this consent withdrawal rate is similar to the 6% to 9.3% reported
in contemporary studies of combined oral contraceptives [11,12].
With any CHC containing EE, one of themost concerning SAEs is VTE.
In our safety database of 2843 women who used the SA/EE CVS in clin-
ical trials, we observed four cases of VTE. Since two of the four cases oc-
curred in women with a BMI N29.0 kg/m2, a high BMI may have
contributed to VTE risk. Notably, the estimated VTE risk of 10.8/10,000
WY in women with BMI ≤29.0 kg/m2 is similar to other vaginal and
transdermal CHC products (3–12 cases per 10,000 WY) [13,14]. No
VTEs occurred in the non-US subgroup, representing 48% of the total
study population with a lower mean weight and BMI. Even though a
trend for increased BMI has occurred over the recent decades and
mostly in the US [15], many previous phase 3 trials of approved CHCs
excluded women with BMI N29 kg/m2. As a result of discontinuing en-
rollment ofwomenwith BMI N29.0 kg/m2, the sample size of obese sub-
jects completing 13 cycles was signiﬁcantly reduced, thereby limiting
the safety conclusions in this subgroup. We could not estimate the
rate of VTEs among women with a BMI N29.0 kg/m2 due to the small
number of women in this group. No VTEs were observed in our studies
of SA-only formulations including 1463 subjects with 1558WY of expo-
sure, suggesting no risk attribution to the progestin SA [16].
The beneﬁt–risk balance for contraceptive steroids is generally pos-
itive with regard to VTE, particularly when compared with that of preg-
nancy [17]. Pregnancy increases the risk of VTE as much or more than
CHCs as the overall incidence of pregnancy-associated VTE is 5 to 65
cases per 10,000WY [17]. Data are conﬂicting between prospective, ac-
tive surveillance studies reporting no difference in VTE risk among dif-
ferent CHC formulations [13] and observational and database studies
suggesting an increase in VTE risk with some combinations [17]. This
discrepancy may be explained by different study designs and the fact
that some observational studies do not adjust for important risk factors
such as overweight, family history of thrombosis and smoking. Indeed
height, weight and obesity are independent risk factors for VTE, and
this risk is further enhanced in obese women using CHCs [18].
Three safety studies evaluated the effect of the SA/EE CVS and of EE
vaginal delivery on hepatic protein synthesis. In one substudy [5], we
found that CVS use for up to 13 cycles slightly changed plasma factor
VIII, ﬁbrinogen and protein S from baseline, but all remained within the
normal range. However, sex hormone binding globulin (SHBG) levels in-
creased above the normal range by cycle 6. Women not using CHCs be-
fore the CVS had greater changes versus recent CHC users whose
baseline values were already higher with previous EE exposure [5].
Somemeasuredhemostasis variables and SHBGwere affecteddiffer-
ently between groups in a comparative, 3-month study of the SA/EE
150/13CVS versus the LNG/EE 150/30OC,most likely because of the dif-
ference in androgenicity of the progestins. SHBG increased more in SA/
EE users than in LNG/EE users as LNG transactivates the androgen re-
ceptor while SA does not [3,19,20]; however, SHBG is not a VTE risk fac-
tor [21,22]. For eight coagulation parameters, including coagulation
activity, prothrombin fragment 1+2 and D-dimer, mean values with
the pilot SA/EE CVS and LNG/EE OC were within their normal reference
ranges, except for factors VII-t and VIII, which were slightly elevated
with the CVS [20].
A third, randomized, crossover, single-center study of 14 postmeno-
pausal women observed no differences in angiotensinogen, SHBG or
clotting factors between EE 15 mcg orally and an EE-only vaginal ring
[7]. Thus, the effects of EE-containing CHCs on hemostatic variables
and estrogen-sensitive liver proteins are largely related to EE, indepen-
dent of delivery route, and precautions for all EE-containing oral contra-
ceptives, including the CVS, should be the same.
In conclusion, we found the overall SA/EE CVS safety data to be
within expectations based on established outcomes with existingCHCs, although data are limited for obese women. Women with
known risk factors for VTE are at risk of thrombosis that may be en-
hanced by any EE-containing contraceptive. Given the safety proﬁle re-
ported here, the marketed product Annovera™ (TherapeuticsMD, Boca
Raton, FL, USA)will have the same precautions as required for other EE-
containing CHCs.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.contraception.2019.02.001.Acknowledgments
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